Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab
Objective To examine the concurrent validity and discrimination of criteria for modified minimal disease activity (MDA) in peripheral spondyloarthritis (SpA) following filter principles of Outcome Measures in Rheumatology (OMERACT) and to determine predictors of modified MDA response. Methods Four m...
Gespeichert in:
| Veröffentlicht in: | Arthritis care & research (2010) 2022-02, Vol.74 (2), p.259-267 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 267 |
|---|---|
| container_issue | 2 |
| container_start_page | 259 |
| container_title | Arthritis care & research (2010) |
| container_volume | 74 |
| creator | Coates, Laura C. Abraham, Sonya Tillett, William Mease, Philip J. Ramiro, Sofia Wu, Tianshuang Wang, Xin Pangan, Aileen L. Song, In‐Ho |
| description | Objective
To examine the concurrent validity and discrimination of criteria for modified minimal disease activity (MDA) in peripheral spondyloarthritis (SpA) following filter principles of Outcome Measures in Rheumatology (OMERACT) and to determine predictors of modified MDA response.
Methods
Four modified MDA versions were derived in the ABILITY‐2 study using the Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index or the Leeds Enthesitis Index (LEI) while excluding psoriasis. To assess concurrent validity, modified MDA versions were correlated with Peripheral Spondyloarthritis Response Criteria (PSpARC) remission, Ankylosing Spondylitis Disease Activity Score showing inactive disease (ASDAS ID), and physician global assessment of disease activity. Treatment discrimination was assessed between adalimumab and placebo at week 12. Multiple logistic regression was used to determine baseline predictors of long‐term modified MDA responses and sustained modified MDA.
Results
The 4 modified MDA versions showed a stronger positive correlation with PSpARC remission (rtet > 0.95) versus ASDAS ID (rtet > 0.75) at week 12 and years 1–3 and were able to show discrimination (P |
| doi_str_mv | 10.1002/acr.24442 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2443881996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2443881996</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3882-127f677b44500a16a7e5c63443832484f06349f3a3f1fe725006078b68b2acee3</originalsourceid><addsrcrecordid>eNp10U1LHDEcBvBQLFWsh34BCXjRw2reJpM5Lqu2BUsXa2lvIZP5h43MTNYk07IfwO_d2LEehOaSF355CHkQ-kDJOSWEXRgbz5kQgr1BB4xWdCFkpfZe1uLnPjpK6Z6UwZlSvHmH9jlreE2oPECPa4guxMGMFrAZO7yO0HmbQ0w4OPzFj34wPb70CUwCvLTZ__J5h28hbcNYTvyI1yZ7GHPCP3ze4BLotxuI5da3QrpdH0zMm-izT_gugsnQzXLZmd4P02Da9-itM32Co-f5EH2_vrpbfVrcfP34ebW8WViuFFtQVjtZ160QFSGGSlNDZSUXgivOhBKOlE3juOGOOqhZUZLUqpWqZcYC8EN0OuduY3iYIGU9-GSh780IYUqaPUUp2jSy0JNX9D5McSyv00wyJmilWFXU2axsDClFcHoby4fFnaZEP9WjSz36bz3FHj8nTu0A3Yv8V0YBFzP47XvY_T9JL1e3c-QfMGaZHw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2622415825</pqid></control><display><type>article</type><title>Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>Coates, Laura C. ; Abraham, Sonya ; Tillett, William ; Mease, Philip J. ; Ramiro, Sofia ; Wu, Tianshuang ; Wang, Xin ; Pangan, Aileen L. ; Song, In‐Ho</creator><creatorcontrib>Coates, Laura C. ; Abraham, Sonya ; Tillett, William ; Mease, Philip J. ; Ramiro, Sofia ; Wu, Tianshuang ; Wang, Xin ; Pangan, Aileen L. ; Song, In‐Ho</creatorcontrib><description>Objective
To examine the concurrent validity and discrimination of criteria for modified minimal disease activity (MDA) in peripheral spondyloarthritis (SpA) following filter principles of Outcome Measures in Rheumatology (OMERACT) and to determine predictors of modified MDA response.
Methods
Four modified MDA versions were derived in the ABILITY‐2 study using the Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index or the Leeds Enthesitis Index (LEI) while excluding psoriasis. To assess concurrent validity, modified MDA versions were correlated with Peripheral Spondyloarthritis Response Criteria (PSpARC) remission, Ankylosing Spondylitis Disease Activity Score showing inactive disease (ASDAS ID), and physician global assessment of disease activity. Treatment discrimination was assessed between adalimumab and placebo at week 12. Multiple logistic regression was used to determine baseline predictors of long‐term modified MDA responses and sustained modified MDA.
Results
The 4 modified MDA versions showed a stronger positive correlation with PSpARC remission (rtet > 0.95) versus ASDAS ID (rtet > 0.75) at week 12 and years 1–3 and were able to show discrimination (P < 0.001). Responsiveness was shown at week 12; significantly more patients receiving adalimumab versus placebo achieved all 4 versions of modified MDA. Approximately 40–60% of patients treated with adalimumab achieved modified MDA using the LEI or SPARCC enthesitis index at years 1–3. Achieving modified MDA response after 12 weeks of adalimumab treatment was a robust positive predictor of attaining long‐term modified MDA through 3 years (odds ratio [OR] 11.38–27.13 for modified MDA using the LEI; OR 17.98–37.85 for modified MDA using the SPARCC enthesitis index).
Conclusion
All 4 versions of modified MDA showed concurrent validity and discriminated well between adalimumab and placebo treatment groups. Early modified MDA response is a more consistent predictor of long‐term modified MDA achievement than baseline characteristics. The 5 of 6 versions of modified MDA could be an appropriate treatment target in patients with peripheral SpA.</description><identifier>ISSN: 2151-464X</identifier><identifier>EISSN: 2151-4658</identifier><identifier>DOI: 10.1002/acr.24442</identifier><identifier>PMID: 32937016</identifier><language>eng</language><publisher>Boston, USA: Wiley Periodicals, Inc</publisher><subject>Adalimumab - therapeutic use ; Ankylosing spondylitis ; Antirheumatic Agents - therapeutic use ; Arthritis ; Discrimination ; Double-Blind Method ; Humans ; Inflammatory diseases ; Monoclonal antibodies ; Outcome Assessment, Health Care ; Patients ; Placebos ; Psoriasis ; Remission ; Remission (Medicine) ; Rheumatic diseases ; Rheumatology ; Spondylarthritis - drug therapy ; TNF inhibitors ; Validity</subject><ispartof>Arthritis care & research (2010), 2022-02, Vol.74 (2), p.259-267</ispartof><rights>2020 The Authors. published by Wiley Periodicals LLC on behalf of American College of Rheumatology.</rights><rights>2020 The Authors. Arthritis Care & Research published by Wiley Periodicals LLC on behalf of American College of Rheumatology.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3882-127f677b44500a16a7e5c63443832484f06349f3a3f1fe725006078b68b2acee3</citedby><cites>FETCH-LOGICAL-c3882-127f677b44500a16a7e5c63443832484f06349f3a3f1fe725006078b68b2acee3</cites><orcidid>0000-0002-6620-0457 ; 0000-0002-4756-663X ; 0000-0002-8899-9087</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Facr.24442$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Facr.24442$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32937016$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Coates, Laura C.</creatorcontrib><creatorcontrib>Abraham, Sonya</creatorcontrib><creatorcontrib>Tillett, William</creatorcontrib><creatorcontrib>Mease, Philip J.</creatorcontrib><creatorcontrib>Ramiro, Sofia</creatorcontrib><creatorcontrib>Wu, Tianshuang</creatorcontrib><creatorcontrib>Wang, Xin</creatorcontrib><creatorcontrib>Pangan, Aileen L.</creatorcontrib><creatorcontrib>Song, In‐Ho</creatorcontrib><title>Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab</title><title>Arthritis care & research (2010)</title><addtitle>Arthritis Care Res (Hoboken)</addtitle><description>Objective
To examine the concurrent validity and discrimination of criteria for modified minimal disease activity (MDA) in peripheral spondyloarthritis (SpA) following filter principles of Outcome Measures in Rheumatology (OMERACT) and to determine predictors of modified MDA response.
Methods
Four modified MDA versions were derived in the ABILITY‐2 study using the Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index or the Leeds Enthesitis Index (LEI) while excluding psoriasis. To assess concurrent validity, modified MDA versions were correlated with Peripheral Spondyloarthritis Response Criteria (PSpARC) remission, Ankylosing Spondylitis Disease Activity Score showing inactive disease (ASDAS ID), and physician global assessment of disease activity. Treatment discrimination was assessed between adalimumab and placebo at week 12. Multiple logistic regression was used to determine baseline predictors of long‐term modified MDA responses and sustained modified MDA.
Results
The 4 modified MDA versions showed a stronger positive correlation with PSpARC remission (rtet > 0.95) versus ASDAS ID (rtet > 0.75) at week 12 and years 1–3 and were able to show discrimination (P < 0.001). Responsiveness was shown at week 12; significantly more patients receiving adalimumab versus placebo achieved all 4 versions of modified MDA. Approximately 40–60% of patients treated with adalimumab achieved modified MDA using the LEI or SPARCC enthesitis index at years 1–3. Achieving modified MDA response after 12 weeks of adalimumab treatment was a robust positive predictor of attaining long‐term modified MDA through 3 years (odds ratio [OR] 11.38–27.13 for modified MDA using the LEI; OR 17.98–37.85 for modified MDA using the SPARCC enthesitis index).
Conclusion
All 4 versions of modified MDA showed concurrent validity and discriminated well between adalimumab and placebo treatment groups. Early modified MDA response is a more consistent predictor of long‐term modified MDA achievement than baseline characteristics. The 5 of 6 versions of modified MDA could be an appropriate treatment target in patients with peripheral SpA.</description><subject>Adalimumab - therapeutic use</subject><subject>Ankylosing spondylitis</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis</subject><subject>Discrimination</subject><subject>Double-Blind Method</subject><subject>Humans</subject><subject>Inflammatory diseases</subject><subject>Monoclonal antibodies</subject><subject>Outcome Assessment, Health Care</subject><subject>Patients</subject><subject>Placebos</subject><subject>Psoriasis</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Rheumatic diseases</subject><subject>Rheumatology</subject><subject>Spondylarthritis - drug therapy</subject><subject>TNF inhibitors</subject><subject>Validity</subject><issn>2151-464X</issn><issn>2151-4658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp10U1LHDEcBvBQLFWsh34BCXjRw2reJpM5Lqu2BUsXa2lvIZP5h43MTNYk07IfwO_d2LEehOaSF355CHkQ-kDJOSWEXRgbz5kQgr1BB4xWdCFkpfZe1uLnPjpK6Z6UwZlSvHmH9jlreE2oPECPa4guxMGMFrAZO7yO0HmbQ0w4OPzFj34wPb70CUwCvLTZ__J5h28hbcNYTvyI1yZ7GHPCP3ze4BLotxuI5da3QrpdH0zMm-izT_gugsnQzXLZmd4P02Da9-itM32Co-f5EH2_vrpbfVrcfP34ebW8WViuFFtQVjtZ160QFSGGSlNDZSUXgivOhBKOlE3juOGOOqhZUZLUqpWqZcYC8EN0OuduY3iYIGU9-GSh780IYUqaPUUp2jSy0JNX9D5McSyv00wyJmilWFXU2axsDClFcHoby4fFnaZEP9WjSz36bz3FHj8nTu0A3Yv8V0YBFzP47XvY_T9JL1e3c-QfMGaZHw</recordid><startdate>202202</startdate><enddate>202202</enddate><creator>Coates, Laura C.</creator><creator>Abraham, Sonya</creator><creator>Tillett, William</creator><creator>Mease, Philip J.</creator><creator>Ramiro, Sofia</creator><creator>Wu, Tianshuang</creator><creator>Wang, Xin</creator><creator>Pangan, Aileen L.</creator><creator>Song, In‐Ho</creator><general>Wiley Periodicals, Inc</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6620-0457</orcidid><orcidid>https://orcid.org/0000-0002-4756-663X</orcidid><orcidid>https://orcid.org/0000-0002-8899-9087</orcidid></search><sort><creationdate>202202</creationdate><title>Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab</title><author>Coates, Laura C. ; Abraham, Sonya ; Tillett, William ; Mease, Philip J. ; Ramiro, Sofia ; Wu, Tianshuang ; Wang, Xin ; Pangan, Aileen L. ; Song, In‐Ho</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3882-127f677b44500a16a7e5c63443832484f06349f3a3f1fe725006078b68b2acee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adalimumab - therapeutic use</topic><topic>Ankylosing spondylitis</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis</topic><topic>Discrimination</topic><topic>Double-Blind Method</topic><topic>Humans</topic><topic>Inflammatory diseases</topic><topic>Monoclonal antibodies</topic><topic>Outcome Assessment, Health Care</topic><topic>Patients</topic><topic>Placebos</topic><topic>Psoriasis</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Rheumatic diseases</topic><topic>Rheumatology</topic><topic>Spondylarthritis - drug therapy</topic><topic>TNF inhibitors</topic><topic>Validity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Coates, Laura C.</creatorcontrib><creatorcontrib>Abraham, Sonya</creatorcontrib><creatorcontrib>Tillett, William</creatorcontrib><creatorcontrib>Mease, Philip J.</creatorcontrib><creatorcontrib>Ramiro, Sofia</creatorcontrib><creatorcontrib>Wu, Tianshuang</creatorcontrib><creatorcontrib>Wang, Xin</creatorcontrib><creatorcontrib>Pangan, Aileen L.</creatorcontrib><creatorcontrib>Song, In‐Ho</creatorcontrib><collection>Wiley Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Arthritis care & research (2010)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Coates, Laura C.</au><au>Abraham, Sonya</au><au>Tillett, William</au><au>Mease, Philip J.</au><au>Ramiro, Sofia</au><au>Wu, Tianshuang</au><au>Wang, Xin</au><au>Pangan, Aileen L.</au><au>Song, In‐Ho</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab</atitle><jtitle>Arthritis care & research (2010)</jtitle><addtitle>Arthritis Care Res (Hoboken)</addtitle><date>2022-02</date><risdate>2022</risdate><volume>74</volume><issue>2</issue><spage>259</spage><epage>267</epage><pages>259-267</pages><issn>2151-464X</issn><eissn>2151-4658</eissn><abstract>Objective
To examine the concurrent validity and discrimination of criteria for modified minimal disease activity (MDA) in peripheral spondyloarthritis (SpA) following filter principles of Outcome Measures in Rheumatology (OMERACT) and to determine predictors of modified MDA response.
Methods
Four modified MDA versions were derived in the ABILITY‐2 study using the Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index or the Leeds Enthesitis Index (LEI) while excluding psoriasis. To assess concurrent validity, modified MDA versions were correlated with Peripheral Spondyloarthritis Response Criteria (PSpARC) remission, Ankylosing Spondylitis Disease Activity Score showing inactive disease (ASDAS ID), and physician global assessment of disease activity. Treatment discrimination was assessed between adalimumab and placebo at week 12. Multiple logistic regression was used to determine baseline predictors of long‐term modified MDA responses and sustained modified MDA.
Results
The 4 modified MDA versions showed a stronger positive correlation with PSpARC remission (rtet > 0.95) versus ASDAS ID (rtet > 0.75) at week 12 and years 1–3 and were able to show discrimination (P < 0.001). Responsiveness was shown at week 12; significantly more patients receiving adalimumab versus placebo achieved all 4 versions of modified MDA. Approximately 40–60% of patients treated with adalimumab achieved modified MDA using the LEI or SPARCC enthesitis index at years 1–3. Achieving modified MDA response after 12 weeks of adalimumab treatment was a robust positive predictor of attaining long‐term modified MDA through 3 years (odds ratio [OR] 11.38–27.13 for modified MDA using the LEI; OR 17.98–37.85 for modified MDA using the SPARCC enthesitis index).
Conclusion
All 4 versions of modified MDA showed concurrent validity and discriminated well between adalimumab and placebo treatment groups. Early modified MDA response is a more consistent predictor of long‐term modified MDA achievement than baseline characteristics. The 5 of 6 versions of modified MDA could be an appropriate treatment target in patients with peripheral SpA.</abstract><cop>Boston, USA</cop><pub>Wiley Periodicals, Inc</pub><pmid>32937016</pmid><doi>10.1002/acr.24442</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6620-0457</orcidid><orcidid>https://orcid.org/0000-0002-4756-663X</orcidid><orcidid>https://orcid.org/0000-0002-8899-9087</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2151-464X |
| ispartof | Arthritis care & research (2010), 2022-02, Vol.74 (2), p.259-267 |
| issn | 2151-464X 2151-4658 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2443881996 |
| source | MEDLINE; Wiley Online Library |
| subjects | Adalimumab - therapeutic use Ankylosing spondylitis Antirheumatic Agents - therapeutic use Arthritis Discrimination Double-Blind Method Humans Inflammatory diseases Monoclonal antibodies Outcome Assessment, Health Care Patients Placebos Psoriasis Remission Remission (Medicine) Rheumatic diseases Rheumatology Spondylarthritis - drug therapy TNF inhibitors Validity |
| title | Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T16%3A15%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Performance%20and%20Predictors%20of%20Minimal%20Disease%20Activity%20Response%20in%20Patients%20With%20Peripheral%20Spondyloarthritis%20Treated%20With%20Adalimumab&rft.jtitle=Arthritis%20care%20&%20research%20(2010)&rft.au=Coates,%20Laura%20C.&rft.date=2022-02&rft.volume=74&rft.issue=2&rft.spage=259&rft.epage=267&rft.pages=259-267&rft.issn=2151-464X&rft.eissn=2151-4658&rft_id=info:doi/10.1002/acr.24442&rft_dat=%3Cproquest_cross%3E2443881996%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2622415825&rft_id=info:pmid/32937016&rfr_iscdi=true |